Rheumatology (Oxford, England) · 2025
Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Poggi Claire, Hachulla Eric, Karras Alexandre, Briantais Antoine, Ravaiau Camille, Gobert Pierre, Deroux Alban, Nicolas Sarah, Belfeki Nabil, François Hélène, Groh Matthieu, London Jonathan, Campagne Julien, Allain Jean-Sébastien, Dernis Emmanuelle, Durel Cécile-Audrey, Le Gallou Thomas, Curie Alexandre, Kerschen Philippe, Gensous Noémie, Reboux Anne-Hélène, Béhal Hélène, Terrier Benjamin, Quéméneur Thomas
Аннотация
OBJECTIVES: Rituximab (RTX) and glucocorticoids are the first-line treatment for essential (EM) and connective tissue disease (CTD)-related mixed cryoglobulinemia vasculitis (CryoVas). Data on long-term outcomes of these CryoVas are lacking. We aimed to describe the prognosis of patients with EM and CTD-related CryoVas.
METHODS: We conducted a retrospective study on patients with EM or CTD-related CryoVas in remission after RTX-based therapy.
RESULTS: We included 63 patients with a median follow-up of 58 months (IQR, 33-88 months). Relapse rates were 23% at 1 year, 42% at 2 years and 71% at 5 years after the initial flare. In univariate analysis, factors associated with relapse were purpura [HR, 2.2; 95% confidence interval (CI), 1.1-4.4; P = 0.02] and a previous flare of CryoVas (HR, 1.9; 95% CI, 1.0-3.7; P = 0.04). Maintenance therapy was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1-0.9; P = 0.03), but not of late relapse (HR, 2.0; 95% CI, 0.7-5.7; P = 0.21). In multivariable analysis, patients without purpura or previous flare remained at lower risk of relapse than those with at least one of the two (HR, 3.6; 95%CI, 1.6-8.2; P = 0.002). Maintenance regimen was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1-0.9; P = 0.03).
CONCLUSION: In patients with EM and CTD-related CryoVas who received RTX as induction therapy, relapses were frequent and associated with purpura and a previous flare but were reduced with maintenance therapy.
METHODS: We conducted a retrospective study on patients with EM or CTD-related CryoVas in remission after RTX-based therapy.
RESULTS: We included 63 patients with a median follow-up of 58 months (IQR, 33-88 months). Relapse rates were 23% at 1 year, 42% at 2 years and 71% at 5 years after the initial flare. In univariate analysis, factors associated with relapse were purpura [HR, 2.2; 95% confidence interval (CI), 1.1-4.4; P = 0.02] and a previous flare of CryoVas (HR, 1.9; 95% CI, 1.0-3.7; P = 0.04). Maintenance therapy was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1-0.9; P = 0.03), but not of late relapse (HR, 2.0; 95% CI, 0.7-5.7; P = 0.21). In multivariable analysis, patients without purpura or previous flare remained at lower risk of relapse than those with at least one of the two (HR, 3.6; 95%CI, 1.6-8.2; P = 0.002). Maintenance regimen was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1-0.9; P = 0.03).
CONCLUSION: In patients with EM and CTD-related CryoVas who received RTX as induction therapy, relapses were frequent and associated with purpura and a previous flare but were reduced with maintenance therapy.